News
Verona’s ensifentrine meets primary endpoint
Verona Pharma has announced its top-line phase 3 ENHANCE-2 trial results evaluating nebulised ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Verona Pharma has announced its top-line phase 3 ENHANCE-2 trial results evaluating nebulised ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD).